Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 4/20 | 0.59 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL747402 | 0.88 | CA1 (0.46) | ESR1ESR2LMNAALDH1A1POLB | |
| SCHEMBL752176 | 0.85 | ESR1 (0.43) | ESR1ESR2LMNAALDH1A1POLB | |
| SCHEMBL752255 | 0.83 | POLB (0.41) | ESR1ESR2LMNAALDH1A1POLB | |
| SCHEMBL749975 | 0.82 | ESR1 (0.42) | ESR1ESR2LMNA | |
| SCHEMBL751637 | 0.82 | LMNA (0.40) | ESR1ESR2LMNAALDH1A1POLB | |
| SCHEMBL6723079 | 0.74 | ESR1 (1.00) | ESR1ESR2MEN1KMT2AEPHX2 | |
| SCHEMBL6716517 | 0.72 | ESR2 (1.00) | ESR1ESR2ALDH1A1MEN1KMT2A | |
| SCHEMBL6716444 | 0.71 | ESR2 (0.87) | ESR1ESR2ALDH1A1POLBMEN1 | |
| SCHEMBL23257728 | 0.70 | LMNA (0.60) | LMNAALDH1A1POLBMEN1KMT2A | |
| SCHEMBL11792294 | 0.69 | SLC6A4 (0.70) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9604960-B2 | Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof | ALBANY MOLECULAR RESEARCH, INC. (US) | 2017-03-28 | — | — | US | disclosed |
| US-9034899-B2 | Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof | ALBANY MOLECULAR RESEARCH, INC. (US) | 2015-05-19 | — | — | US | disclosed |
| US-20150126517-A1 | ARYL, HETEROARYL, AND HETEROCYCLE SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF | APOLLO ADMINISTRATIVE AGENCY LLC, AS SUCCESSOR AGENT | 2015-05-07 | — | — | US | disclosed |
| EP-2429295-B1 | ARYL, HETEROARYL, AND HETEROCYCLE SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF | ALBANY MOLECULAR RES INC (US) | 2013-12-25 | — | — | EP | disclosed |
| EP-2429295-A1 | ARYL, HETEROARYL, AND HETEROCYCLE SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF | Albany Molecular Research, Inc. (US) | 2012-03-21 | — | — | EP | disclosed |
| WO-2010132437-A1 | ARYL, HETEROARYL, AND HETEROCYCLE SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF | ALBANY MOLECULAR RESEARCH, INC. (US) | 2010-11-18 | — | — | WO | disclosed |
| US-20100292242-A1 | ARYL, HETEROARYL, AND HETEROCYCLE SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF | ALBANY MOLECULAR RESEARCH, INC. (US) | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292242-A1 | ARYL, HETEROARYL, AND HETEROCYCLE SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF | NLN, HTR3B, HTR2C | ESR1 3912/4885ESR2 2433/4885LMNA 2931/4885 |
| US-20150126517-A1 | ARYL, HETEROARYL, AND HETEROCYCLE SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF | NLN, HTR3B, HTR2C | ESR1 3912/4885ESR2 2433/4885LMNA 2931/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.